Early-stage funding Inso Bio has secured pre-seed financing and state grants totaling approximately $2.8M, signaling investor confidence and potential readiness for customer-facing pilots or partnerships to de-risk early adoption.

Novel capture tech The solid-phase DNA capture platform using microfluidics promises simpler, cheaper automation and faster workflows, presenting a compelling value proposition for customers seeking scalable genomic sample prep and multiomic integration.

Target customers With a focus on genomic medicine and research, potential sales targets include academic labs, biotech startups, and contract research organizations needing accessible, on-chip sample processing compatible with long DNA fragments.

Strategic partnerships Collaboration opportunities with universities, life science incubators, and regional biotech clusters could accelerate validation, provide grant-backed pilots, and help scale adoption through co-development or early access programs.

Competitive positioning Positioning against traditional bead- and column-based methods highlights reduced setup, lower cost, and built-in multiomics, offering a differentiator for procurement teams seeking modern, end-to-end sample-to-answer solutions.